Table 2 Relationship between P53 expression in NSCLC and clinical pathological factors (Chi-square test).
|  | Patients | P53 high expression (%) | P value | χ2 value |
|---|---|---|---|---|
Gender | ||||
Male | 89 | 47 (52.81%) | Â | Â |
Female | 34 | 24 (70.59%) | 0.102 | 3.187 |
Age | ||||
≤ 60 | 71 | 41 (57.75%) |  |  |
> 60 | 52 | 30 (57.69%) | 1.000 | 0.000 |
Histology | ||||
Squamous cancer | 72 | 41 (56.94%) | Â | Â |
Adenocarcinoma | 51 | 30 (58.82%) | 0.855 | 0.043 |
Differentiation | ||||
Well | 16 | 9 (56.25%) | Â | Â |
Moderate | 55 | 33 (60%) | Â | Â |
Poor | 52 | 29 (55.77%) | 0.899 | 0.212 |
Stage | ||||
I–II | 56 | 25 (44.64%) |  |  |
III | 67 | 46 (68.66%) | 0.01 | 7.208 |
mTOR expression | ||||
High | 72 | 51 (70.83%) | Â | Â |
Low | 51 | 20 (39.22%) | 0.001 | 12.229 |
AMPK expression | ||||
High | 49 | 19 (38.78%) | Â | Â |
Low | 74 | 52 (70.27%) | 0.001 | 11.983 |
IL-7 expression | ||||
High | 89 | 62 (69.66%) | Â | Â |
Low | 34 | 9 (26.47%) | 0.000 | 18.807 |
IL-7R expression | ||||
High | 81 | 58 (71.6%) | Â | Â |
Low | 42 | 13 (30.95%) | 0.000 | 18.731 |
